• 1
    Wen PY, Black PM, Loeffler JS. Metastatic brain cancer. In: deVita V, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: Lippincott, Williams & Wilkins; 2001: 2655-2670.
  • 2
    Greenberg H, Chandler WF, Sandler HM. Brain metastases. In: Greenberg H, Chandler WF, Sandler HM, eds. Brain Tumors. New York: Oxford University Press; 1999: 299-317.
  • 3
    Mehta MP, Tremont-Lukats I. Radiosurgery for single and multiple brain metastasis. In: Sawaya R, ed. Intracranial Metastases: Current Management Strategies. Malden, MA: Blackwell Publishing, Futura Division; 2004: 139-164.
  • 4
    Sundstrom JT, Minn H, Lertola KK, Nordman E. Prognosis of patients treated for intracranial metastases with whole-brain irradiation. Ann Med. 1998; 30: 296-299.
  • 5
    Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with 1 to 3 brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004; 363: 1665-1672.
  • 6
    Rades D, Kieckebusch S, Haatanen T, Lohynska R, Dunst J, Schild SE. Surgical resection followed by whole brain radiotherapy versus whole brain radiotherapy alone for single brain metastasis. Int J Radiat Oncol Biol Phys. 2008; 70: 1319-1324.
  • 7
    Rades D, Pluemer A, Veninga T, Hanssens P, Dunst J, Schild SE. Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases. Cancer. 2007; 110: 2285-2292.
  • 8
    Rades D, Dziggel L, Haatanen T, et al. Scoring systems to estimate intracerebral control and survival rates of patients irradiated for brain metastases. Int J Radiat Oncol Biol Phys. 2011; 80: 1122-1127.
  • 9
    Joiner MC, Van der Kogel AJ. The linear-quadratic approach to fractionation and calculation of isoeffect relationships. In: Steel GG, ed. Basic Clinical Radiobiology. New York: Oxford University Press; 1997: 106-112.
  • 10
    Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in 3 Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997; 37: 745-751.
  • 11
    Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to 3 other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008; 70: 510-514.
  • 12
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 13
    Trotti A, Byhardt R, Stetz J, et al. Common Toxicity Criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 47: 13-47.
  • 14
    Eyre HJ, Ohlsen JD, Frank J, et al. Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment of metastatic cancer to the brain. J Neuro-Oncol. 1984; 2: 325-330.
  • 15
    DeAngelis LM, Currie VE, Kim JH, et al. The combined use of radiation therapy and loniamide in the treatment of brain metastases. J Neuro-Oncol. 1989; 7: 241-247.
  • 16
    Komarnicky LT, Phillips TL, Martz K, Asbell S, Isaacson S, Urtasun R. A randomized phase III protocol for the evaluation of misonidazole combined with radiation in the treatment of patients with brain metastases (RTOG-7916). Int J Radiat Oncol Biol Phys. 1991; 20: 53-58.
  • 17
    Mehta MP, Rodrigus P, Terhaard CH, et al. Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol. 2003; 21: 2529-2536.
  • 18
    Ushio Y, Arita N, Hayakawa T, et al. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery. 1991; 28: 201-205.
  • 19
    Postmus PE, Haaxma-Reiche H, Smit EF, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole brain radiotherapy—a phase II study of the European Organization for the Research and Treatment of Lung Cancer Cooperative Group. J Clin Oncol. 2000; 18: 3400-3408.
  • 20
    Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination for inoperable brain metastasis of non-small cell lung cancer: Groupe Francaise de Pneumo-Cancerologie (GFPC) protocol 95-1. Ann Oncol. 2001; 12: 59-67.
  • 21
    Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol. 2002; 20: 3644-3650.
  • 22
    Mornex F, Thomas L, Mohr P, et al. Randomized phase III trial of fotemustine plus whole brain irradiation in cerebral metastases of melanoma. Cancer Radiother. 2003; 7: 1-8.
  • 23
    Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 1981; 7: 891-895.
  • 24
    Chatani M, Matayoshi Y, Masaki N, Inoue T. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol. 1994; 170: 155-161.
  • 25
    Rades D, Haatanen T, Schild SE, Dunst J. Dose escalation beyond 30 grays in 10 fractions for patients with multiple brain metastases. Cancer. 2007; 110: 1345-1350.
  • 26
    Rades D, Heisterkamp C, Schild SE. Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose? Int J Radiat Oncol Biol Phys. 2010; 78: 398-403.
  • 27
    Heisterkamp C, Haatanen T, Schild SE, Rades D. Dose escalation in patients receiving whole-brain radiotherapy for brain metastases from colorectal cancer. Strahlenther Onkol. 2010; 186: 70-75.
  • 28
    Rades D, Heisterkamp C, Huttenlocher S, et al. Dose escalation of whole-brain radiotherapy for brain metastases from melanoma. Int J Radiat Oncol Biol Phys. 2010; 77: 537-541.